1. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma
   Yuki Misawa et al, 2017, Tumour Biol. CrossRef
2. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
   Mayte Delgado-Ureña et al, 2018, J Transl Med CrossRef
3. Bevacizumab as a potential anti‐angiogenic therapy in schistosomiasis: A double‐edged, but adjustable weapon
   Marwa A. Hasby Saad et al, 2020, Parasite Immunol CrossRef
4. Synthesis, In Silico Study, and Anti-Cancer Activity of Thiosemicarbazone Derivatives
   Belay Zeleke Sibuh et al, 2021, Biomedicines CrossRef
5. Emerging trends in immunotoxin targeting cancer stem cells
   Belay Zeleke Sibuh et al, 2022, Toxicology in Vitro CrossRef
6. Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens.
   Helen P Kourea et al, 2021, Cancer Res Treat CrossRef
7. Axl and Vascular Endothelial Growth Factor Receptors Exhibit Variations in Membrane Localization and Heterogeneity Across Monolayer and Spheroid High-Grade Serous Ovarian Cancer Models
   Yingye Fang et al, 2023, GEN Biotechnology CrossRef
8. VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway
   Chunsik Lee et al, 2023, Sig Transduct Target Ther CrossRef
9. null
   Esteban Acosta-Ramos et al, 2024 CrossRef